Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative (Q35680026)

9 August 2017

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative (English)

1 reference

9 August 2017

phase I clinical trial

0 references

personalized medicine

1 reference

14

Razelle Kurzrock

1 reference

Apostolia Maria Tsimberidou

9 August 2017

1

object named as

Apostolia-Maria Tsimberidou

1 reference

9 August 2017

8

Aung Naing

1 reference

9 August 2017

9

Filip Janku

1 reference

9 August 2017

Nancy G Iskander

2

1 reference

9 August 2017

David S Hong

3

1 reference

9 August 2017

Jennifer J Wheler

4

1 reference

9 August 2017

Gerald S Falchook

5

1 reference

9 August 2017

Siqing Fu

6

1 reference

9 August 2017

Sarina Piha-Paul

7

1 reference

9 August 2017

Rajyalakshmi Luthra

10

1 reference

9 August 2017

Yang Ye

11

1 reference

9 August 2017

Sijin Wen

12

1 reference

9 August 2017

Donald Berry

13

1 reference

9 August 2017

language of work or name

English

0 references

publication date

10 September 2012

1 reference

9 August 2017

11

1 reference

inferred from page(s)

published in

Clinical Cancer Research

1 reference

9 August 2017

18

1 reference

9 August 2017

22

1 reference

9 August 2017

6373-6383

1 reference

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Crizotinib--latest champion in the cancer wars?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Multi-sample pooling and illumina genome analyzer sequencing methods to determine gene sequence variation for database development

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

International network of cancer genome projects

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

The landscape of somatic copy-number alteration across human cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

The PI3K pathway as drug target in human cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Application of COLD-PCR for improved detection of KRAS mutations in clinical samples

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

High frequency of mutations of the PIK3CA gene in human cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Mutations of the BRAF gene in human cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4454458

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

25 September 2018

1 reference

12 December 2020

Cancer genomics: from discovery science to personalized medicine

1 reference

12 December 2020

Medicine. Personalized cancer diagnostics

1 reference

12 December 2020

Impact of genomics on personalized cancer medicine

1 reference

12 December 2020

10.1158/1078-0432.CCR-12-1627

Identifiers

DOI

1 reference

9 August 2017

1 reference

9 August 2017

1 reference